Sickle cell disease tied to significantly elevated risk of retinal vascular occlusion: Study
A study by Kaufmann and team examined the risk of big artery retinal vascular occlusion (RVO) in a large national US database and found that individuals with sickle cell disease (SCD) who had hemoglobin SS (HbSS) posed a much greater risk. The key findings of this study were published in the Ophthalmology Retina journal.
SCD affects about 100,000 individuals in the US, and it costs the healthcare system over $3 billion a year. Despite RVO has been documented in published research to occur in SCD patients, including bilateral occlusions, the actual risk of RVO is still unclear. Also, no research has assessed the risk of RVO in the US population as a whole or in strata based on hemoglobin mutation previously. This study assessed the risk of venous and arterial RVO in individuals with different β-globin mutations by this study.
94 million patients were included in the cross-sectional and retrospective cohort research from 2006 to 2024 using the national database of the TriNetX US Collaborative Network. The patients with sickle cell were included using the ICD-10 codes, such as sickle cell trait, hemoglobin SCD (HbSC), or sickle cell disease (SCD) (HbSS). Propensity score matching was used to create matched control cohorts based on factors such as age, race, sex, ethnicity, diabetes, smoking, dyslipidemia, hypertension, and obesity. Hereditary corneal dystrophies served as a negative control for the outcomes of interest, which comprised any RVO, central RVO (CRVO), branch RVO (BRVO), CRAO, and branch retinal artery blockage (BRAO).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.